DM
NVCR icon

Deerfield Management’s NovoCure NVCR Stock Holding History

Deerfield Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-825,119
Closed -$14.7M – 165
2025
Q2 		$14.7M Buy
825,119
+175,000
+27% +$3.05M 0.27% 61
2025
Q1 		$11.6M Buy
+650,119
New +$14.8M 0.23% 66

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deerfield Management's NVCR Position: Q3 2025 in Review

Deerfield Management sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 825,119 shares — an estimated $14.7M sold.

Deerfield Management first reported a position in NVCR in Q1 2025 and held it in 2 quarters. The position peaked at $14.7M in Q2 2025. 245 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Deerfield Management reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
  • Deerfield Management sold 825,119 NovoCure shares in Q3 2025, an estimated $14.7M.
  • Deerfield Management first reported a position in NovoCure in Q1 2025 and held it in 2 quarters.
  • Deerfield Management's NovoCure position peaked at $14.7M in Q2 2025.
  • 245 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Deerfield Management's 13F filing for Q3 2025, filed 14 Nov 2025.